SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77649.00
883.08 (1.15%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Nectar Lifesciences Ltd.	Q V PT	199 Small Cap	10.20 (-0.29%)	N/A	0.34	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Panacea Biotec Ltd.	Q V+ PT	2,540 Small Cap	422 (1.75%)	N/A	8.91	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Nephrocare Health Services Ltd.	Q V+ PT	6,927 Small Cap	699.25 (1.51%)	N/A	7.27	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Solara Active Pharma Sciences Ltd.	Q V PT	2,446 Small Cap	505.35 (-0.33%)	N/A	1.92	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Fischer Medical Ventures Ltd.	Q V PT	2,411 Small Cap	35.99 (-2.31%)	N/A	7.72	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Sigachi Industries Ltd.	Q V+ PT	971 Small Cap	25.92 (1.97%)	N/A	2.04	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Health X Platform Ltd.	Q V PT	968 Small Cap	306.30 (0.71%)	N/A	3.57	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Suven Life Sciences Ltd.	Q V+ PT	8,314 Small Cap	308.40 (4.81%)	N/A	4.74	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	KMC Speciality Hospitals (India) Ltd.	Q V PT	2,124 Small Cap	129.45 (-0.61%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Hikal Ltd.	Q V+ PT	2,676 Small Cap	220.55 (1.61%)	N/A	2.23	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Themis Medicare Ltd.	Q V PT	973 Small Cap	108.80 (3.03%)	N/A	3.62	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,783 Small Cap	214.70 (2.73%)	4.37	5.09	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Natco Pharma Ltd.	Q V PT	16,561 Small Cap	935.90 (1.22%)	11.68	1.8	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Lincoln Pharmaceuticals Ltd.	Q V PT	1,161 Small Cap	580.10 (0.10%)	13.21	1.53	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Shalby Ltd.	Q V PT	1,742 Small Cap	163.55 (1.39%)	15.43	1.4	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Syncom Formulations (India) Ltd.	Q V PT	1,216 Small Cap	13.14 (1.55%)	16	2.95	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Wanbury Ltd.	Q V+ PT	1,092 Small Cap	311.65 (-0.27%)	16.51	7.56	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Krsnaa Diagnostics Ltd.	Q V+ PT	1,731 Small Cap	534.95 (0.26%)	17.06	1.77	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,376 Small Cap	363.95 (-1.17%)	18.39	4.56	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Aarti Drugs Ltd.	Q V PT	3,717 Small Cap	408.80 (0.38%)	19.07	2.4	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Fabtech Technologies Ltd.	Q V PT	664 Small Cap	149.50 (0.10%)	19.26	1.7	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Anuh Pharma Ltd.	Q V PT	802 Small Cap	79.53 (-0.60%)	19.54	2.28	12.30	12.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Indoco Remedies Ltd.	Q V+ PT	2,105 Small Cap	229.25 (0.50%)	20.11	1.92	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Lupin Ltd.	Q V PT	1,09,494 Mid Cap	2,457.70 (2.63%)	20.53	4.89	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Fermenta Biotech Ltd.	Q V PT	1,343 Small Cap	450 (-1.37%)	20.89	3.2	3.85	-0.38	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Zydus Lifesciences Ltd.	Q V PT	1,09,686 Mid Cap	1,124.70 (2.28%)	21.76	4.22	13.52	14.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	3B Blackbio Dx Ltd.	Q V PT	1,112 Small Cap	1,275 (-1.63%)	22.56	4.08	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	FDC Ltd.	Q V PT	6,639 Small Cap	412.30 (1.12%)	23.22	2.66	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Unichem Laboratories Ltd.	Q V PT	3,763 Small Cap	533.85 (-0.11%)	23.67	1.44	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Alembic Pharmaceuticals Ltd.	Q V+ PT	16,085 Small Cap	808.05 (-1.25%)	23.84	2.83	6.37	-8.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Artemis MedicareServ	301.05	8.60%
Divis Laboratories	7,780	4.85%
Suven Life Sciences	308.40	4.81%
SMS Pharmaceuticals	397.50	4.36%
Dr. Lal Pathlabs	1,882.80	4.24%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Hester Biosciences	2,460.10	-2.57%
Fischer Medical	35.99	-2.31%
3B Blackbio Dx	1,275	-1.63%
Fermenta Biotech	450	-1.37%
Kwality Pharma	2,556	-1.29%

News about Top Pharma Companies in India

Jul, 2026

Indoco Remedies - Quaterly Results

The total revenue for the quarter ended June 2026 remained nearly unchanged at Rs. 4089.70 millions.The Total Profit for the quarter ended June 2026 of Rs. 823.20 millions grew from Rs.-280.70 millionsOP of the company witnessed a marginal growth to 466.80 millions from 204.00 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	4089.70	3943.10	3.72	4089.70	3943.10	3.72	16860.70	15181.90	11.06
Other Income	44.70	55.80	-19.89	44.70	55.80	-19.89	296.40	184.80	60.39
PBIDT	466.80	204.00	128.82	466.80	204.00	128.82	1867.90	1465.20	27.48
Interest	227.50	236.10	-3.64	227.50	236.10	-3.64	885.00	566.30	56.28
PBDT	1212.70	-32.10	-3877.88	1212.70	-32.10	-3877.88	954.30	908.80	5.01
Depreciation	280.50	252.00	11.31	280.50	252.00	11.31	1069.00	982.50	8.80
PBT	932.20	-284.10	-428.12	932.20	-284.10	-428.12	-114.70	-73.70	55.63
TAX	109.00	-3.40	-3305.88	109.00	-3.40	-3305.88	-58.10	13.60	-527.21
Deferred Tax	3.40	-3.40	-200.00	3.40	-3.40	-200.00	-87.30	13.60	-741.91
PAT	823.20	-280.70	-393.27	823.20	-280.70	-393.27	-56.60	-87.30	-35.17
Equity	184.60	184.50	0.05	184.60	184.50	0.05	184.60	184.50	0.05
PBIDTM(%)	11.41	5.17	120.62	11.41	5.17	120.62	11.08	9.65	14.79

Jul, 2026

Alembic Pharma moves up on getting USFDA’s final approval for Prucalopride Tablets

Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults

Jul, 2026

Alembic Pharma gets USFDA’s final approval for Prucalopride Tablets

Prucalopride tablets are serotonin-4 receptor agonist indicated for the treatment of chronic idiopathic constipation in adults

Jul, 2026

Indoco Remedies informs about change in management

Indoco Remedies has informed that the Board of Directors in its Meeting held today i.e. 28th July, 2026 has considered and approved Re-appointment of Aditi Panandikar as the Managing Director of the Company for the period of 5 years commencing from 15th February, 2027 to 14th February, 2032, subject to the approval of the shareholders in the ensuing AGM; and appointment of Sudhir Kadam as Senior Management Personnel designated as Sr. Vice President (Human Capital) of the Company with effect from 28th July, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that the Company’s wholly owned subsidiary, Panacea Biotec Pharma (‘PBPL’), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax (‘GST’), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ?4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Solara Active Pharma - Quaterly Results

The revenue zoomed 19.57% to Rs. 3816.00 millions for the quarter ended June 2026 as compared to Rs. 3191.50 millions during the corresponding quarter last year.Profit for the quarter ended June 2026 rises by 61.35% to Rs. 169.90 millions from Rs. 105.30 millions.OP of the company witnessed a marginal growth to 639.30 millions from 580.10 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3816.00	3191.50	19.57	3816.00	3191.50	19.57	13689.80	12837.60	6.64
Other Income	19.20	9.80	95.92	19.20	9.80	95.92	58.90	91.40	-35.56
PBIDT	639.30	580.10	10.21	639.30	580.10	10.21	1925.70	2129.80	-9.58
Interest	202.30	239.00	-15.36	202.30	239.00	-15.36	942.40	1148.10	-17.92
PBDT	437.00	341.10	28.11	437.00	341.10	28.11	924.40	981.70	-5.84
Depreciation	267.10	235.80	13.27	267.10	235.80	13.27	996.80	992.50	0.43
PBT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
Equity	480.60	443.40	8.39	480.60	443.40	8.39	445.10	402.50	10.58
PBIDTM(%)	16.75	18.18	-7.83	16.75	18.18	-7.83	14.07	16.59	-15.21

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	199 Crore
2	Panacea Biotec Ltd.	2,540 Crore
3	Nephrocare Health Services Ltd.	6,927 Crore
4	Solara Active Pharma Sciences Ltd.	2,446 Crore
5	Fischer Medical Ventures Ltd.	2,411 Crore
6	Sigachi Industries Ltd.	971 Crore
7	Health X Platform Ltd.	968 Crore
8	Suven Life Sciences Ltd.	8,314 Crore
9	KMC Speciality Hospitals (India) Ltd.	2,124 Crore
10	Hikal Ltd.	2,676 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,880	1,86,354	86.14	22.16	44.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,458	1,09,494	20.53	4.89	11.88	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,669	67,559	30.92	4.83	22.42	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,782	94,987	97.82
Sai Life Sciences Ltd. (S)	Very Good	1,310	27,605	57.56
Aurobindo Pharma Ltd. (M)	Very Good	1,591	89,212	37.52
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,880	1,86,354	35.15
Lupin Ltd. (M)	Somewhat Good	2,458	1,09,494	22.15
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,310	27,605	80.84	11.01	42.51	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	13.54
Mankind Pharma Ltd. (M)	Very Good	2,602	1,08,129	53.07	6.61	33.20	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,125	1,09,686	21.76	4.22	13.36	13.52
Lupin Ltd. (M)	Somewhat Good	2,458	1,09,494	20.53	4.89	11.88	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,458	1,09,494	20.53	4.89	11.88	32.37
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,144	94,790	29.42	2.48	15.11	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,125	1,09,686	21.76	4.22	13.36	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,984	4,74,397	41.33	5.68	23.70	14.41

You have 8 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Indoco Remedies - Quaterly Results

Alembic Pharma moves up on getting USFDA’s final approval for Prucalopride Tablets

Alembic Pharma gets USFDA’s final approval for Prucalopride Tablets

Indoco Remedies informs about change in management

Panacea Biotec informs about disclosure

Solara Active Pharma - Quaterly Results

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.